Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma

(1) Background: First-line therapy in fit MCL patients may comprise high-dose chemotherapy (HDCT) with autologous transplantation to consolidate remission before maintenance treatment. However, optimization of HDCT is an unmet clinical need given the substantial relapse rate of first-line treatment,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-03, Vol.15 (7), p.2091
Hauptverfasser:	Huwyler, Fabrizio, Kunz, Rebekka, Bacher, Ulrike, Hoffmann, Michèle, Novak, Urban, Daskalakis, Michael, Banz, Yara, Pabst, Thomas
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Anemia Antimitotic agents Antineoplastic agents Bortezomib Cancer Care and treatment Chemotherapy Development and progression Disease prevention Dosage and administration Feasibility studies Hematology Lymphoma Lymphomas Mantle cell lymphoma Medical research Medicine, Experimental Patients Peripheral neuropathy Remission Remission (Medicine) Thrombocytopenia Transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!